Related Experiment Videos
Lower prolactin bioactivity in unmedicated schizophrenic patients
M D Warner1, A M Walker, D C D'Souza
1Department of Psychiatry, University of Michigan Medical Center, Ann Arbor, MI 48109, USA.
Psychiatry Research
|July 7, 2001
Summary
Schizophrenic patients exhibit lower prolactin (PRL) bioactivity (BA) and a reduced BA/RIA ratio compared to controls. This suggests distinct PRL molecular forms in schizophrenia, potentially linked to dopamine system or medication effects.
Area of Science:
- Endocrinology
- Neuropsychiatry
- Molecular Biology
Background:
- Previous studies indicated abnormalities in the bioassay (BA) to radioimmunoassay (RIA) ratio of prolactin (PRL) in schizophrenia.
- This ratio suggests potential differences in PRL molecular forms between patients and healthy individuals.
Purpose of the Study:
- To investigate prolactin (PRL) molecular forms in neuroleptic-free male schizophrenic patients compared to male controls.
- To assess differences in PRL bioassay (BA) and radioimmunoassay (RIA) values and their ratio.
Main Methods:
- Radioimmunoassay (RIA) and Nb(2) bioassay (BA) techniques were used to measure PRL levels.
- Seven neuroleptic-free male patients with schizophrenia and seven male control subjects were studied.
Main Results:
- The schizophrenic group showed significantly lower PRL bioassay (BA) values compared to normal controls.
- A significantly lower PRL ratio of BA/RIA was observed in schizophrenic patients.
Conclusions:
- The findings support the hypothesis that schizophrenic patients possess different molecular forms of prolactin (PRL).
- This molecular difference may stem from a dysregulated tuberoinfundibular dopamine system or chronic neuroleptic medication effects.